Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

EPO Patent Bulletin: Therapeutic Peptides from Frzb Protein Netrin-Like Domain

The European Patent Office has published patent application EP4153611A1 concerning therapeutic peptides derived from the netrin-like domain of the Frzb protein. The publication details potential therapeutic applications and lists the applicants and inventors.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Publication EP4125376A1: Antimicrobial Peptides

The European Patent Office published patent application EP4125376A1 on March 11, 2026, concerning antimicrobial peptides developed by Materias S.r.l. This publication details specific peptide sequences and their potential applications.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent EP4204092A1: Multi-specific Antigen Binding Molecules Targeting HIV

The European Patent Office has published patent application EP4204092A1, filed by Gilead Sciences, Inc., concerning multi-specific antigen binding molecules targeting HIV. The patent details methods of use for these molecules in treating or preventing HIV infections.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent EP4188944A1: Biostimulant Peptides for Agriculture

The European Patent Office has published patent application EP4188944A1 concerning biostimulant and bioprotective peptides for use in agriculture. The patent was filed by Materias S.r.l. and published on March 11, 2026.

Routine Notice Agriculture
Favicon for changeflow.com

EPO Patent EP3915587A1: Improved Cell-Targeting Binding Molecule

The European Patent Office has published patent application EP3915587A1 for an "Improved Cell-Targeting Binding Molecule" filed by Sapreme Technologies B.V. The patent publication date is March 11, 2026, and it covers applications in various European designated states.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Human Anti-Human CD22 CAR Patent Application EP4130040A1

The European Patent Office has published patent application EP4130040A1 concerning a fully human anti-human CD22 chimeric antigen receptor and its application, filed by Nanjing Iaso Biotechnology Co., Ltd. The publication date is March 11, 2026.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Bulletin - Chimeric Antigen Receptor-Modified NK-92 Cells

The European Patent Office (EPO) published patent application EP4097219A1 concerning chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors. The application was filed by ImmunityBio, Inc. and lists Hermes J. Garban et al. as inventors. The publication date is March 11, 2026.

Routine Notice Healthcare
Favicon for changeflow.com

Immunocytokines and Uses Thereof Patent EP4263836A1

The European Patent Office has published patent application EP4263836A1 concerning immunocytokines and their uses, filed by Immunowake Inc. The publication date is March 11, 2026. This patent application relates to advancements in biotechnology and pharmaceutical applications.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Publication EP3988565A1: T Cell Receptors

The European Patent Office published patent application EP3988565A1 concerning T Cell Receptors on March 11, 2026. The application was filed by USWM CT, LLC and lists Nicholas Tribble, William Lawrance, and Eleanor Bagg as inventors. This publication relates to advancements in peptide-based therapeutics.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent EP4039703A1: Chimeric Antigen Receptor and Anti C-Met Antibody

The European Patent Office has published patent application EP4039703A1 concerning a Chimeric Antigen Receptor comprising an anti-C-Met antibody or antigen binding fragment thereof. The patent was published on March 11, 2026, with Helixmith Co., Ltd. listed as the applicant.

Routine Notice Healthcare

Showing 3211–3220 of 29,967 changes

1 320 321 322 323 324 2997

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.